. . . . "Sou\u010Dasn\u00E9 pod\u00E1v\u00E1n\u00ED vankomycinu a\u00A0anestetik bylo prov\u00E1zeno eryt\u00E9mem, n\u00E1valy podobn\u00FDmi reakc\u00EDm na histamin a\u00A0anafylaktoidn\u00EDmi reakcemi.\nBylo hl\u00E1\u0161eno, \u017Ee \u010Detnost reakc\u00ED souvisej\u00EDc\u00EDch s\u00A0infuz\u00ED se zvy\u0161uje p\u0159i sou\u010Dasn\u00E9m pod\u00E1v\u00E1n\u00ED anestetik. \u00DA\u010Dinky souvisej\u00EDc\u00ED s\u00A0infuz\u00ED lze minimalizovat pod\u00E1n\u00EDm vankomycinu v\u00A0podob\u011B 60minutov\u00E9 infuze p\u0159ed anestetickou indukc\u00ED.\nJe-li indikov\u00E1no soub\u011B\u017En\u00E9 \u010Di n\u00E1sledn\u00E9 syst\u00E9mov\u00E9 nebo lok\u00E1ln\u00ED pod\u00E1n\u00ED jin\u00FDch potenci\u00E1ln\u011B ototoxick\u00FDch, neurotoxick\u00FDch \u010Di nefrotoxick\u00FDch l\u00E9\u010Div, jako jsou amfotericin B, aminoglykosidy, bacitracin, polymyxin B, kolistin, viomycin a\u00A0cisplatina, je t\u0159eba pacienta pe\u010Dliv\u011B sledovat.\nP\u0159i sou\u010Dasn\u00E9m pod\u00E1n\u00ED vankomycinu a\u00A0neuromuskul\u00E1rn\u00EDch blok\u00E1tor\u016F se zvy\u0161uje riziko neuromuskul\u00E1rn\u00ED blokace.\n"@cs . "004.005" . . "4.5\tInterakce s\u00A0jin\u00FDmi l\u00E9\u010Div\u00FDmi p\u0159\u00EDpravky a jin\u00E9 formy interakce"@cs . .